Dyne Therapeutics launches $300M share offering for genetically driven disease therapeutics, led by Morgan Stanley, Jefferies, Stifel, Guggenheim Securities.
Dyne Therapeutics launches $300M share offering; clinical-stage muscle disease company raising funds to advance therapeutics for genetically driven diseases. Offering to be led by Morgan Stanley, Jefferies, Stifel, Guggenheim Securities as joint book-running managers, with Oppenheimer & Co., Raymond James as co-managers. The offering is subject to market conditions.
May 20, 2024
3 Articles